Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation

Makoto Murata, Hideki Nakasone, Junya Kanda, Takahiko Nakane, Tatsuo Furukawa, Takahiro Fukuda, Takehiko Mori, Shuichi Taniguchi, Tetsuya Eto, Kazuteru Ohashi, Masayuki Hino, Masami Inoue, Hiroyasu Ogawa, Yoshiko Atsuta, Tokiko Nagamura-Inoue, Hiromasa Yabe, Yasuo Morishima, Hisashi Sakamaki, Ritsuro Suzuki

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Systemic corticosteroid therapy is recommended as a first-line treatment for acute graft-versus-host disease (GVHD). We performed a retrospective study to identify the factors affecting the response of grade II to IV acute GVHD to systemic corticosteroid therapy using the Japanese national registry data for patients who received first allogeneic hematopoietic cell transplantation with bone marrow (BM) (n=1955), peripheral blood stem cells (PBSCs) (n=642), or umbilical cord blood (UCB) (n=839). Of 3436 patients, 2190 (63.7%) showed improvement of acute GVHD to first-line therapy with corticosteroids. Various factors were identified to predict corticosteroid response. Interestingly, UCB (versus HLA-matched related BM) transplantation was significantly associated with a higher probability of improvement, whereas HLA-matched unrelated BM and HLA-mismatched stem cell sources other than UCB were significantly associated with a lower probability of improvement. HLA-matched related PBSC transplantation was not significantly different from HLA-matched related BM transplantation. Patients without improvement from corticosteroid therapy had a 2.5-times higher nonrelapse mortality and a .6-times lower overall survival rate. The present study demonstrated, for the first time, a higher probability of improvement in grade II to IV acute GVHD with systemic corticosteroid therapy in patients after UCB transplantation than in those after BM and PBSC transplantation. A prospective study is warranted.

Original languageEnglish
Pages (from-to)1183-1189
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number8
DOIs
Publication statusPublished - 2013 Aug

Fingerprint

Cell Transplantation
Graft vs Host Disease
Japan
Adrenal Cortex Hormones
Fetal Blood
Bone Marrow Transplantation
Peripheral Blood Stem Cell Transplantation
Therapeutics
Bone Marrow
Registries
Stem Cells
Survival Rate
Retrospective Studies
Transplantation
Prospective Studies
Mortality

Keywords

  • Acute graft-versus-host disease
  • Cord blood transplantation
  • Corticosteroid

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy : An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation. / Murata, Makoto; Nakasone, Hideki; Kanda, Junya; Nakane, Takahiko; Furukawa, Tatsuo; Fukuda, Takahiro; Mori, Takehiko; Taniguchi, Shuichi; Eto, Tetsuya; Ohashi, Kazuteru; Hino, Masayuki; Inoue, Masami; Ogawa, Hiroyasu; Atsuta, Yoshiko; Nagamura-Inoue, Tokiko; Yabe, Hiromasa; Morishima, Yasuo; Sakamaki, Hisashi; Suzuki, Ritsuro.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 8, 08.2013, p. 1183-1189.

Research output: Contribution to journalArticle

Murata, M, Nakasone, H, Kanda, J, Nakane, T, Furukawa, T, Fukuda, T, Mori, T, Taniguchi, S, Eto, T, Ohashi, K, Hino, M, Inoue, M, Ogawa, H, Atsuta, Y, Nagamura-Inoue, T, Yabe, H, Morishima, Y, Sakamaki, H & Suzuki, R 2013, 'Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation', Biology of Blood and Marrow Transplantation, vol. 19, no. 8, pp. 1183-1189. https://doi.org/10.1016/j.bbmt.2013.05.003
Murata, Makoto ; Nakasone, Hideki ; Kanda, Junya ; Nakane, Takahiko ; Furukawa, Tatsuo ; Fukuda, Takahiro ; Mori, Takehiko ; Taniguchi, Shuichi ; Eto, Tetsuya ; Ohashi, Kazuteru ; Hino, Masayuki ; Inoue, Masami ; Ogawa, Hiroyasu ; Atsuta, Yoshiko ; Nagamura-Inoue, Tokiko ; Yabe, Hiromasa ; Morishima, Yasuo ; Sakamaki, Hisashi ; Suzuki, Ritsuro. / Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy : An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 8. pp. 1183-1189.
@article{fa2268eb124247378d150919654b0dd2,
title = "Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation",
abstract = "Systemic corticosteroid therapy is recommended as a first-line treatment for acute graft-versus-host disease (GVHD). We performed a retrospective study to identify the factors affecting the response of grade II to IV acute GVHD to systemic corticosteroid therapy using the Japanese national registry data for patients who received first allogeneic hematopoietic cell transplantation with bone marrow (BM) (n=1955), peripheral blood stem cells (PBSCs) (n=642), or umbilical cord blood (UCB) (n=839). Of 3436 patients, 2190 (63.7{\%}) showed improvement of acute GVHD to first-line therapy with corticosteroids. Various factors were identified to predict corticosteroid response. Interestingly, UCB (versus HLA-matched related BM) transplantation was significantly associated with a higher probability of improvement, whereas HLA-matched unrelated BM and HLA-mismatched stem cell sources other than UCB were significantly associated with a lower probability of improvement. HLA-matched related PBSC transplantation was not significantly different from HLA-matched related BM transplantation. Patients without improvement from corticosteroid therapy had a 2.5-times higher nonrelapse mortality and a .6-times lower overall survival rate. The present study demonstrated, for the first time, a higher probability of improvement in grade II to IV acute GVHD with systemic corticosteroid therapy in patients after UCB transplantation than in those after BM and PBSC transplantation. A prospective study is warranted.",
keywords = "Acute graft-versus-host disease, Cord blood transplantation, Corticosteroid",
author = "Makoto Murata and Hideki Nakasone and Junya Kanda and Takahiko Nakane and Tatsuo Furukawa and Takahiro Fukuda and Takehiko Mori and Shuichi Taniguchi and Tetsuya Eto and Kazuteru Ohashi and Masayuki Hino and Masami Inoue and Hiroyasu Ogawa and Yoshiko Atsuta and Tokiko Nagamura-Inoue and Hiromasa Yabe and Yasuo Morishima and Hisashi Sakamaki and Ritsuro Suzuki",
year = "2013",
month = "8",
doi = "10.1016/j.bbmt.2013.05.003",
language = "English",
volume = "19",
pages = "1183--1189",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy

T2 - An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation

AU - Murata, Makoto

AU - Nakasone, Hideki

AU - Kanda, Junya

AU - Nakane, Takahiko

AU - Furukawa, Tatsuo

AU - Fukuda, Takahiro

AU - Mori, Takehiko

AU - Taniguchi, Shuichi

AU - Eto, Tetsuya

AU - Ohashi, Kazuteru

AU - Hino, Masayuki

AU - Inoue, Masami

AU - Ogawa, Hiroyasu

AU - Atsuta, Yoshiko

AU - Nagamura-Inoue, Tokiko

AU - Yabe, Hiromasa

AU - Morishima, Yasuo

AU - Sakamaki, Hisashi

AU - Suzuki, Ritsuro

PY - 2013/8

Y1 - 2013/8

N2 - Systemic corticosteroid therapy is recommended as a first-line treatment for acute graft-versus-host disease (GVHD). We performed a retrospective study to identify the factors affecting the response of grade II to IV acute GVHD to systemic corticosteroid therapy using the Japanese national registry data for patients who received first allogeneic hematopoietic cell transplantation with bone marrow (BM) (n=1955), peripheral blood stem cells (PBSCs) (n=642), or umbilical cord blood (UCB) (n=839). Of 3436 patients, 2190 (63.7%) showed improvement of acute GVHD to first-line therapy with corticosteroids. Various factors were identified to predict corticosteroid response. Interestingly, UCB (versus HLA-matched related BM) transplantation was significantly associated with a higher probability of improvement, whereas HLA-matched unrelated BM and HLA-mismatched stem cell sources other than UCB were significantly associated with a lower probability of improvement. HLA-matched related PBSC transplantation was not significantly different from HLA-matched related BM transplantation. Patients without improvement from corticosteroid therapy had a 2.5-times higher nonrelapse mortality and a .6-times lower overall survival rate. The present study demonstrated, for the first time, a higher probability of improvement in grade II to IV acute GVHD with systemic corticosteroid therapy in patients after UCB transplantation than in those after BM and PBSC transplantation. A prospective study is warranted.

AB - Systemic corticosteroid therapy is recommended as a first-line treatment for acute graft-versus-host disease (GVHD). We performed a retrospective study to identify the factors affecting the response of grade II to IV acute GVHD to systemic corticosteroid therapy using the Japanese national registry data for patients who received first allogeneic hematopoietic cell transplantation with bone marrow (BM) (n=1955), peripheral blood stem cells (PBSCs) (n=642), or umbilical cord blood (UCB) (n=839). Of 3436 patients, 2190 (63.7%) showed improvement of acute GVHD to first-line therapy with corticosteroids. Various factors were identified to predict corticosteroid response. Interestingly, UCB (versus HLA-matched related BM) transplantation was significantly associated with a higher probability of improvement, whereas HLA-matched unrelated BM and HLA-mismatched stem cell sources other than UCB were significantly associated with a lower probability of improvement. HLA-matched related PBSC transplantation was not significantly different from HLA-matched related BM transplantation. Patients without improvement from corticosteroid therapy had a 2.5-times higher nonrelapse mortality and a .6-times lower overall survival rate. The present study demonstrated, for the first time, a higher probability of improvement in grade II to IV acute GVHD with systemic corticosteroid therapy in patients after UCB transplantation than in those after BM and PBSC transplantation. A prospective study is warranted.

KW - Acute graft-versus-host disease

KW - Cord blood transplantation

KW - Corticosteroid

UR - http://www.scopus.com/inward/record.url?scp=84880441178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880441178&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.05.003

DO - 10.1016/j.bbmt.2013.05.003

M3 - Article

C2 - 23676716

AN - SCOPUS:84880441178

VL - 19

SP - 1183

EP - 1189

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -